{
  "input": {
    "mode": "build_counterchain",
    "query": {
      "entity": "Familial pulmonary fibrosis",
      "relation": "contraindication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_abatacept",
          "name": "Abatacept"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_anakinra",
          "name": "Anakinra"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_azathioprine",
          "name": "Azathioprine"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_bosentan",
          "name": "Bosentan"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_cyclophosphamide",
          "name": "Cyclophosphamide"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_daclizumab",
          "name": "Daclizumab"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_nintedanib",
          "name": "Nintedanib"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_pirfenidone",
          "name": "Pirfenidone"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_rituximab",
          "name": "Rituximab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_teriflunomide",
          "name": "Teriflunomide"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 1
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "n_ot1",
          "type": "Target",
          "label": "Increased Fibrosis Risk",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot2",
          "type": "Target",
          "label": "Immunosuppression",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv1",
          "type": "Phenotype",
          "label": "Exacerbation of Pulmonary Fibrosis",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_abatacept",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "已知风险与疾病进展相关"
        },
        {
          "source": "drug_abatacept",
          "target": "n_ot2",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "可能导致免疫抑制，增加感染风险"
        },
        {
          "source": "n_ot1",
          "target": "n_adv1",
          "relation": "causes",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "可能加重肺纤维化临床表现"
        },
        {
          "source": "n_ot2",
          "target": "n_adv1",
          "relation": "causes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "免疫抑制可能导致病情恶化"
        },
        {
          "source": "n_adv1",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.9,
          "agent": "Skeptic",
          "rationale": "风险存在可能抵消潜在益处"
        }
      ],
      "merge": [],
      "set_weights": [],
      "conflict_hotspots": [
        {
          "topic": "免疫抑制与肺部疾病进展风险",
          "pro_nodes": [
            "n_ot1",
            "n_ot2"
          ],
          "con_nodes": [
            "n_adv1"
          ],
          "note": "急性对肺部症状的改善可能掩盖长远风险"
        }
      ]
    },
    "counterclaims": [
      {
        "id": "K1",
        "text": "免疫抑制可能导致肺部感染，加重肺纤维化，风险严重",
        "confidence": "high"
      },
      {
        "id": "K2",
        "text": "已知副作用表明药物在肺纤维化患者中的使用需谨慎",
        "confidence": "medium"
      }
    ],
    "assumptions_challenged": [
      "阿巴塔塞特在肺纤维化患者中的安全性是否确立",
      "长期效果是否足以覆盖短期获益"
    ],
    "falsification_tests": [
      "是否有数据支持该药物在肺纤维化患者中的有效性与安全性",
      "是否存在会加重肺症状的副作用记录"
    ],
    "next_focus_for_pi": [
      "要求 Proponent 提供在这一特定疾病背景下的临床结果",
      "重新审视免疫抑制对肺部病情影响的相关数据"
    ]
  }
}